Form 4: Opus Genetics President Benjamin Yerxa Receives Stock Grant

Benjamin Yerxa, President of Opus Genetics, was granted 332,800 shares of common stock on November 7, 2024, as part of a restricted stock unit agreement.

Summary

• On November 7, 2024, Benjamin R Yerxa, President of Opus Genetics, received a grant of 332,800 shares of common stock.
• These shares are in the form of restricted stock units (RSUs) that will vest in four equal installments.
• The vesting dates are the first, second, third, and fourth anniversaries of October 22, 2024, contingent upon Yerxa's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral positive.

Positives

• The stock grant aligns the President's interests with the long-term success of Opus Genetics.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the stock grant is subject to the performance of Opus Genetics' stock.
• If Yerxa leaves the company before the RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The vesting schedule suggests a commitment to long-term value creation at Opus Genetics.

Industry Context

Stock grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• Shareholders may view the stock grant positively as it aligns management's interests with the company's long-term performance.

Key Dates